By Scott Tzu with Parke Shall
When a company is in a distressed situation, a lot of times it’s not going to come out and tell the public that it is looking at a reorganization or considering filing bankruptcy. As investors, we are often left to draw our own conclusions based on piecemeal that we can obtain regarding the company in question. We believe the signs and signals continue to indicate to us that Concordia Healthcare (NASDAQ:CXRX) is not a stock to be in, has limited turnaround prospects, and could very well be heading for restructuring.
By now, most readers will find themselves familiar with the CXRX story, but for those who are not, we will give you a small briefing. Concordia is one of many pharmaceutical companies that tried to expand by rolling up other corporations once the cost of debt became very cheap. It used a hybrid style pricing model, where it raised the price of several key drugs after acquiring them in order to bet it all on the compan y’s future cash flows instead of the mounting pile of debt that the company was accruing. When presenting earnings each quarter, CXRX used similar non-GAAP accounting treatments to give the impression that acquisition costs and one time costs would not be a factor. Now, like Valeant (NYSE:VRX), as questions start to rise about the company’s product line, all eyes turn to the balance sheet, which is in severe distress.
Best Cheap Stocks To Watch For 2017: DRDGOLD Limited(DRD)
- [By Lisa Levin]
Tuesday afternoon, the basic materials sector proved to be a source of strength for the market. Leading the sector was strength from Endeavour Silver Corp (NYSE: EXK) and DRDGOLD Ltd. (ADR) (NYSE: DRD).
- [By Lisa Levin]
In trading on Wednesday, basic materials shares fell by 1.27 percent. Meanwhile, top losers in the sector included McEwen Mining Inc (NYSE: MUX), down 12 percent, and DRDGOLD Ltd. (ADR) (NYSE: DRD), down 7 percent.
Best Cheap Stocks To Watch For 2017: SORL Auto Parts Inc.(SORL)
- [By Lisa Levin]
Sorl Auto Parts, Inc. (NASDAQ: SORL) was down, falling around 8 percent to $3.68. Greenridge Global downgraded SORL Auto Parts from Buy to Hold.
- [By Monica Gerson]
Sorl Auto Parts, Inc. (NASDAQ: SORL) is expected to post its quarterly earnings at $0.20 per share on revenue of $55.35 million.
Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.
Best Cheap Stocks To Watch For 2017: Ultragenyx Pharmaceutical Inc.(RARE)
- [By Jon C. Ogg]
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.
- [By Johanna Bennett]
Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.
Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51
The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.
Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.
Leerik analyst Joseph Schwartz called the selloff a buying opportunity.
We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.
Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.
We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.
- [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha) Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha) Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period. Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share. Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement. Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share. Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76. QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share. Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering. Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston